SALES

6 Months Ended

Jun. 30, 2012

SALES [Text Block]

NOTE 13 – SALES

The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the three months ended June 30, 2012 and 2011 are as follows:

		For the three months ended
		June 30, 2012		June 30, 2011
Human Albumin	$	19,539,419	$	21,377,406
Immunoglobulin products:
Human Hepatitis B Immunoglobulin		2,346,915		1,874,504
Human Immunoglobulin for Intravenous Injection		21,239,174		16,084,281
Human Rabies Immunoglobulin		2,116,013		2,451
Human Tetanus Immunoglobulin		1,879,363		1,951,355
Human Immunoglobulin		645,531		-
Placenta Polypeptide		2,509,202		-
Others		190,722		375,461
Total	$	50,466,339	$	41,665,458

The Company’s sales by significant types of product for the six months ended June 30, 2012 and 2011 are as follows:

		For the six months ended
		June 30, 2012		June 30, 2011
Human Albumin	$	45,329,702	$	41,078,992
Immunoglobulin products:
Human Hepatitis B Immunoglobulin		3,606,500		4,090,185
Human Immunoglobulin for Intravenous Injection		36,500,900		26,511,668
Human Rabies Immunoglobulin		3,097,572		752,520
Human Tetanus Immunoglobulin		3,313,399		3,140,291
Human Immunoglobulin		755,630		-
Placenta Polypeptide		4,620,011		-
Others		470,086		562,624
Total	$	97,693,800	$	76,136,280